NCT03822793View on ClinicalTrials.gov

A Dose-response Study of Tranexamic Acid in Total Hip Arthroplasty

PHASE2RecruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

December 7, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Arthropathy of Hip
Interventions
DRUG

Placebo

Patient will receive an intravenous perfusion of NaCl (sodium chloride 9%; placebo) intravenous over 9 minutes, starting at the time of surgical incision.

DRUG

Group 1: perfusion of 300 mg Exacyl

Patient will receive an intravenous perfusion of 300 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.

DRUG

Group 2: perfusion of 500 mg Exacyl

Patient will receive an intravenous perfusion of 500 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.

DRUG

Group 3: perfusion of 1000 mg Exacyl

Patient will receive an intravenous perfusion of 1000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.

DRUG

Group 4: perfusion of 3000 mg Exacyl

Patient will receive an intravenous perfusion of 3000 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.

Trial Locations (1)

Unknown

RECRUITING

CHU Saint-Etienne, Saint-Etienne

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Saint Etienne

OTHER